Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial

BACKGROUND: This study evaluated the cost-effectiveness of replacing standard intravenous therapy (taxane) with oral S-1 therapy for first-line metastatic breast cancer treatment. METHODS: This cost-effectiveness analysis was based on data from a randomized phase III trial (SELECT BC). As cost-effec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Shiroiwa, Takeru, Fukuda, Takashi, Shimozuma, Kojiro, Mouri, Mitsuko, Hagiwara, Yasuhiro, Kawahara, Takuya, Ohsumi, Shozo, Hozumi, Yasuo, Sagara, Yoshiaki, Ohashi, Yasuo, Mukai, Hirofumi
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693567/
https://ncbi.nlm.nih.gov/pubmed/29149882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-017-3774-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados